STOCK TITAN

Lipocine Inc - LPCN STOCK NEWS

Welcome to our dedicated news page for Lipocine (Ticker: LPCN), a resource for investors and traders seeking the latest updates and insights on Lipocine.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lipocine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lipocine's position in the market.

Rhea-AI Summary
Lipocine Inc. (NASDAQ: LPCN) announced Q3 2023 financial results and a corporate update. The company reported a net loss of $6.7 million for Q3 2023, recognized a non-cash minimum guaranteed royalties revenue reversal of $3.1 million, and had $23.8 million of unrestricted cash. Clinical highlights include LPCN 1154's successful meeting with the FDA for postpartum depression treatment and positive topline results from the Phase 2 study of LPCN 1148 in liver cirrhosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
-
Rhea-AI Summary
Lipocine Inc. announced that an abstract on LPCN 1148 has been selected for a late breaking oral presentation at The Liver Meeting® 2023. The presentation will focus on how LPCN 1148 improves sarcopenia and hepatic encephalopathy in patients with cirrhosis. Dr. Arun J. Sanyal will be the presenter. The presentation will take place on November 13, 2023, at 2:45 PM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
conferences clinical trial
-
Rhea-AI Summary
Lipocine Inc. has announced that it has reached an agreement with the FDA on the acceptance criteria for the pivotal study of LPCN 1154, a potential treatment for postpartum depression. The company plans to initiate dosing in the study in Q1'24.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
none
Rhea-AI Summary
Lipocine Inc. will present and meet with investors at the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.8%
Tags
conferences
-
Rhea-AI Summary
Lipocine Inc. to present at Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.6%
Tags
-
Rhea-AI Summary
Lipocine Inc. will present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference on June 26, 2023. The webcast link will be available for 90 days. Lipocine is a biopharmaceutical company focused on treating CNS disorders. They have multiple drug candidates in development and are exploring partnering opportunities. Lipocine's clinical development candidates include LPCN 1154 for postpartum depression, LPCN 2101 for epilepsy, and LPCN 1148 for symptoms associated with liver cirrhosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
conferences
-
Rhea-AI Summary
Lipocine Inc. will present posters on LPCN 1148 and LPCN 1144 at the EASL Congress 2023. The Phase 2 study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled, with results expected in mid-2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
conferences
Lipocine Inc

Nasdaq:LPCN

LPCN Rankings

LPCN Stock Data

30.88M
5.16M
3.03%
9.17%
2.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Salt Lake City

About LPCN

lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.